Combination therapies

Martin Oudega, E. J. Bradbury, M. S. Ramer

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Spinal cord injury (SCI) has multiple consequences, ranging from molecular imbalances to glial scar formation to functional impairments. It is logical to think that a combination of single treatments implemented in the right order and at the right time will be required to repair the spinal cord. However, the single treatments that compose the combination therapy will need to be chosen with caution as many have multiple outcomes that may or may not be synergistic. Single treatments may also elicit unwanted side-effects and/or effects that would decrease the repair potential of other components and/or the entire combination therapy. In this chapter a number of single treatments are discussed with respect to their multiplicity of action. These include strategies to boost growth and survival (such as neurotrophins and cyclic AMP) and strategies to reduce inhibitory factors (such as antimyelin-associated growth inhibitors and digestion of glial scar-associated inhibitors). We also present an overview of combination therapies that have successfully or unsuccessfully been tested in the laboratory using animal models. To effectively design a combination therapy a number of considerations need to be made such as the nature and timing of the treatments and the method for delivery. This chapter discusses these issues as well as considerations related to chronic SCI and the logistics of bringing combination therapies to the clinic.

Original languageEnglish (US)
Pages (from-to)617-636
Number of pages20
JournalHandbook of Clinical Neurology
Volume109
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Spinal Cord Injuries
Neuroglia
Cicatrix
Spinal Cord Regeneration
Therapeutics
Growth Inhibitors
Nerve Growth Factors
Cyclic AMP
Digestion
Animal Models
Growth

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Combination therapies. / Oudega, Martin; Bradbury, E. J.; Ramer, M. S.

In: Handbook of Clinical Neurology, Vol. 109, 2012, p. 617-636.

Research output: Contribution to journalArticle

Oudega, Martin ; Bradbury, E. J. ; Ramer, M. S. / Combination therapies. In: Handbook of Clinical Neurology. 2012 ; Vol. 109. pp. 617-636.
@article{b1d06011e5494f60a7f9f8f8a9fa189f,
title = "Combination therapies",
abstract = "Spinal cord injury (SCI) has multiple consequences, ranging from molecular imbalances to glial scar formation to functional impairments. It is logical to think that a combination of single treatments implemented in the right order and at the right time will be required to repair the spinal cord. However, the single treatments that compose the combination therapy will need to be chosen with caution as many have multiple outcomes that may or may not be synergistic. Single treatments may also elicit unwanted side-effects and/or effects that would decrease the repair potential of other components and/or the entire combination therapy. In this chapter a number of single treatments are discussed with respect to their multiplicity of action. These include strategies to boost growth and survival (such as neurotrophins and cyclic AMP) and strategies to reduce inhibitory factors (such as antimyelin-associated growth inhibitors and digestion of glial scar-associated inhibitors). We also present an overview of combination therapies that have successfully or unsuccessfully been tested in the laboratory using animal models. To effectively design a combination therapy a number of considerations need to be made such as the nature and timing of the treatments and the method for delivery. This chapter discusses these issues as well as considerations related to chronic SCI and the logistics of bringing combination therapies to the clinic.",
author = "Martin Oudega and Bradbury, {E. J.} and Ramer, {M. S.}",
year = "2012",
doi = "10.1016/B978-0-444-52137-8.00038-3",
language = "English (US)",
volume = "109",
pages = "617--636",
journal = "Handbook of Clinical Neurology",
issn = "0072-9752",
publisher = "Elsevier",

}

TY - JOUR

T1 - Combination therapies

AU - Oudega, Martin

AU - Bradbury, E. J.

AU - Ramer, M. S.

PY - 2012

Y1 - 2012

N2 - Spinal cord injury (SCI) has multiple consequences, ranging from molecular imbalances to glial scar formation to functional impairments. It is logical to think that a combination of single treatments implemented in the right order and at the right time will be required to repair the spinal cord. However, the single treatments that compose the combination therapy will need to be chosen with caution as many have multiple outcomes that may or may not be synergistic. Single treatments may also elicit unwanted side-effects and/or effects that would decrease the repair potential of other components and/or the entire combination therapy. In this chapter a number of single treatments are discussed with respect to their multiplicity of action. These include strategies to boost growth and survival (such as neurotrophins and cyclic AMP) and strategies to reduce inhibitory factors (such as antimyelin-associated growth inhibitors and digestion of glial scar-associated inhibitors). We also present an overview of combination therapies that have successfully or unsuccessfully been tested in the laboratory using animal models. To effectively design a combination therapy a number of considerations need to be made such as the nature and timing of the treatments and the method for delivery. This chapter discusses these issues as well as considerations related to chronic SCI and the logistics of bringing combination therapies to the clinic.

AB - Spinal cord injury (SCI) has multiple consequences, ranging from molecular imbalances to glial scar formation to functional impairments. It is logical to think that a combination of single treatments implemented in the right order and at the right time will be required to repair the spinal cord. However, the single treatments that compose the combination therapy will need to be chosen with caution as many have multiple outcomes that may or may not be synergistic. Single treatments may also elicit unwanted side-effects and/or effects that would decrease the repair potential of other components and/or the entire combination therapy. In this chapter a number of single treatments are discussed with respect to their multiplicity of action. These include strategies to boost growth and survival (such as neurotrophins and cyclic AMP) and strategies to reduce inhibitory factors (such as antimyelin-associated growth inhibitors and digestion of glial scar-associated inhibitors). We also present an overview of combination therapies that have successfully or unsuccessfully been tested in the laboratory using animal models. To effectively design a combination therapy a number of considerations need to be made such as the nature and timing of the treatments and the method for delivery. This chapter discusses these issues as well as considerations related to chronic SCI and the logistics of bringing combination therapies to the clinic.

UR - http://www.scopus.com/inward/record.url?scp=84867776666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867776666&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-52137-8.00038-3

DO - 10.1016/B978-0-444-52137-8.00038-3

M3 - Article

C2 - 23098740

AN - SCOPUS:84867776666

VL - 109

SP - 617

EP - 636

JO - Handbook of Clinical Neurology

JF - Handbook of Clinical Neurology

SN - 0072-9752

ER -